A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Public ClinicalTrials.gov record NCT07318558. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Study identification
- NCT ID
- NCT07318558
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 900 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2026
- Primary completion
- Feb 24, 2033
- Completion
- Feb 24, 2033
- Last update posted
- Aug 27, 2026
2026 – 2033
United States locations
- U.S. sites
- 25
- U.S. states
- 19
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama - Birmingham ( Site 0058) | Birmingham | Alabama | 35233 | Recruiting |
| John Muir Health Cancer Center ( Site 0069) | Walnut Creek | California | 94598 | Recruiting |
| Mount Sinai Cancer Center ( Site 0029) | Miami Beach | Florida | 33140 | Recruiting |
| Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) | Orlando | Florida | 32806 | Recruiting |
| Winship Cancer Institute of Emory University ( Site 0037) | Atlanta | Georgia | 30308 | Recruiting |
| Illinois Cancer Specialists (ICS) ( Site 8009) | Arlington Heights | Illinois | 60005 | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0055) | Fort Wayne | Indiana | 46845 | Recruiting |
| Franciscan Health Indianapolis ( Site 0081) | Indianapolis | Indiana | 46237 | Recruiting |
| Women's Cancer Care ( Site 0018) | Covington | Louisiana | 70433 | Recruiting |
| Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0060) | Scarborough | Maine | 04074 | Recruiting |
| Maryland Oncology Hematology, P.A. ( Site 8002) | Columbia | Maryland | 21044 | Recruiting |
| Nebraska Methodist Hospital ( Site 0004) | Omaha | Nebraska | 68114 | Recruiting |
| University Of Nebraska Medical Center ( Site 0035) | Omaha | Nebraska | 68198 | Recruiting |
| The Center of Hope ( Site 0025) | Reno | Nevada | 89511 | Recruiting |
| Womens Cancer Care Associates, LLC ( Site 0023) | Albany | New York | 12208-1743 | Recruiting |
| Duke Cancer Center ( Site 0012) | Durham | North Carolina | 27710 | Recruiting |
| University of Cincinnati Medical Center ( Site 0042) | Cincinnati | Ohio | 45219 | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007) | Tulsa | Oklahoma | 74146 | Recruiting |
| Hospital of the University of Pennsylvania ( Site 0071) | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Women & Infants Hospital ( Site 0001) | Providence | Rhode Island | 02905 | Recruiting |
| West Cancer Center and Research Institute ( Site 0013) | Germantown | Tennessee | 38138 | Recruiting |
| University of Tennessee Medical Center ( Site 0087) | Knoxville | Tennessee | 37920 | Recruiting |
| Henry-Joyce Cancer Clinic ( Site 0011) | Nashville | Tennessee | 37232 | Recruiting |
| Virginia Cancer Specialists (VCS) ( Site 8012) | Fairfax | Virginia | 22031 | Recruiting |
| Virginia Oncology Associates (VOA) ( Site 8013) | Norfolk | Virginia | 23502 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 134 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07318558, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 27, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07318558 live on ClinicalTrials.gov.